Patents by Inventor Outi Hovatta

Outi Hovatta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132838
    Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
    Type: Application
    Filed: August 21, 2023
    Publication date: April 25, 2024
    Inventors: Outi Hovatta, Karl Tryggvason
  • Patent number: 11767509
    Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: September 26, 2023
    Assignee: BioLamina AB
    Inventors: Outi Hovatta, Karl Tryggvason
  • Publication number: 20210139848
    Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
    Type: Application
    Filed: December 30, 2020
    Publication date: May 13, 2021
    Inventors: Outi Hovatta, Karl Tryggvason
  • Patent number: 10889801
    Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: January 12, 2021
    Assignee: BioLamina AB
    Inventors: Outi Hovatta, Karl Tryggvason
  • Publication number: 20170342378
    Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 30, 2017
    Inventors: Karl Tryggvason, Kristian Tryggvason, Outi Hovatta
  • Patent number: 9719066
    Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 1, 2017
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Kristian Tryggvason, Outi Hovatta
  • Publication number: 20150299653
    Abstract: The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells.
    Type: Application
    Filed: December 3, 2013
    Publication date: October 22, 2015
    Inventors: Outi Hovatta, Karl Tryggvason
  • Publication number: 20150191694
    Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.
    Type: Application
    Filed: September 6, 2013
    Publication date: July 9, 2015
    Applicant: BioLamina AB
    Inventors: Karl Tryggvason, Kristian Tryggvason, Outi Hovatta
  • Publication number: 20100081200
    Abstract: The present invention relates to a serum replacement formulation and to a culture medium suitable for the derivation, maintenance and differentiation of stem cells.
    Type: Application
    Filed: December 7, 2009
    Publication date: April 1, 2010
    Inventors: Kristiina Rajala, Marjo-Riitta Suuronen, Outi Hovatta, Heli Skottman
  • Publication number: 20020133835
    Abstract: A composition for in vivo transfection of vertebrate male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. A pharmaceutical preparation and a transfer kit utilize the composition. A method for introducing a polynucleotide into vertebrate male germ cells comprises the administration of the composition to a vertebrate. A method for isolating or selecting transfected cells utilizes a reporter gene, and a method for administering transfected male germ cells utilizes male germ cells which have been transfected in vitro.
    Type: Application
    Filed: November 12, 2001
    Publication date: September 19, 2002
    Inventors: Robert Winston, Carol W. Readhead, Outi Hovatta
  • Publication number: 20020083479
    Abstract: A composition for in vivo transfection of vertebrate male germ cells comprises a nucleic acid or transgene, and a gene delivery system, and optionally a protective internalizing agent, such as an endosomal lytic agent, a virus or a viral component, which is internalized by cells along with the transgene and which enhances gene transfer through the cytoplasm to the nucleus of the male germ cell. A pharmaceutical preparation and a transfer kit utilize the composition. A method for introducing a polynucleotide into vertebrate male germ cells comprises the administration of the composition to a vertebrate. A method for isolating or selecting transfected cells utilizes a reporter gene, and a method for administering transfected male germ cells utilizes male germ cells which have been transfected in vitro.
    Type: Application
    Filed: November 12, 2001
    Publication date: June 27, 2002
    Inventors: Robert Winston, Carol W. Readhead, Outi Hovatta